While adenosine has been demonstrated to drive a tolerogenic DC phenotype, importantly by the downregulation of IL-12, and has been shown to diminish CD103+ DC recruitment in murine models, human data and the effect of adenosine inhibition on DCs in the setting of anti-tumor immunity is yet to be determined (158, 159). This evidence concerns the gene ITGAE and neoplasm.